Enantioselective Syntheses of Heteroyohimbine Natural Product Intermediates
US-2016326183-A1 · Nov 10, 2016 · US
US9604923B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9604923-B2 |
| Application number | US-201414246522-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 7, 2014 |
| Priority date | May 19, 2006 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.
Opening claim text (preview).
We claim: 1. A compound having the following structure: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising: a compound having the following structure: or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
for testing antineoplastic activity · CPC title
to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups · CPC title
to carbon atoms of non-condensed six-membered aromatic rings · CPC title
with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.